Background
UCB, Inc. holds U.S. Patent No. 10,130,589 covering transdermal patches that deliver rotigotine — a dopamine agonist used to treat Parkinson’s disease and restless legs syndrome. A key aspect of UCB’s patent was the use of polyvinylpyrrolidone (PVP) to stabilize rotigotine in its amorphous (non-crystalline) form. The patent claimed specific weight ratios of rotigotine to PVP that kept the drug from crystallizing in the patch, which had been a commercial problem that caused UCB to temporarily withdraw an earlier patch product from the market.
Actavis Laboratories, seeking to market a generic version of the patch, challenged the patent’s validity on obviousness grounds. Actavis pointed to prior art references — the Muller patents — that disclosed rotigotine-PVP formulations with weight ratio ranges that overlapped with the ranges claimed in UCB’s patent. The district court found the patent invalid, and UCB appealed, arguing that the district court misapplied the legal framework for evaluating overlapping-range obviousness and that the claimed formulation produced unexpected results that should have saved the patent.
The Court’s Holding
The Federal Circuit affirmed invalidity. The court clarified the legal standard that applies when prior art discloses a range that overlaps with a claimed range: such an overlap creates a presumption of obviousness. This is distinct from the situation where prior art discloses only a single point within a broader claimed range, which may or may not support a prima facie case depending on the circumstances. When the ranges themselves overlap, the burden shifts to the patentee to rebut the presumption by showing either that the claimed range is critical — meaning the claimed range produces substantially different results than adjacent ranges — or that the claimed range produces new and unexpected results compared to what the prior art would have predicted.
UCB argued that a new formulation of its commercial product (Neupro) represented a changed state of the art that rendered earlier prior art irrelevant, and that the stabilization of the amorphous form constituted unexpected results. The court rejected both arguments. On the state-of-the-art argument, the court found no clear error in the district court’s determination that Neupro’s reformulation did not retroactively eliminate the prior art’s relevance to the obviousness analysis. On unexpected results, the court found that UCB failed to demonstrate that the claimed rotigotine-PVP ratios produced results that would have been genuinely surprising to a skilled formulator — the stabilizing effect of PVP on amorphous drug forms was a known phenomenon in pharmaceutical science.
Key Takeaways
- When prior art discloses ranges that overlap with claimed ranges, a presumption of obviousness arises — this is stronger than the prima facie case that arises when prior art discloses only a single point within a claimed range.
- To overcome this presumption, a patentee must show that the claimed range is critical (produces substantially different results than adjacent ranges) or that the claimed range produces new and unexpected results the prior art would not have predicted.
- A patentee cannot retroactively eliminate prior art from the obviousness analysis by arguing that later commercial developments changed the state of the art at the time of invention.
- Pharmaceutical patent applicants claiming specific formulation ratios should build a robust experimental record demonstrating criticality of the chosen ranges, not merely the utility of the formulation.
Why It Matters
This decision has wide practical importance for pharmaceutical and chemical patent prosecution. Many drug formulation patents claim specific ranges of ingredient ratios — concentrations, pH levels, molecular weights, particle sizes, and similar parameters. When prior art exists that discloses overlapping ranges (even if the exact claimed range is not explicitly disclosed), this decision confirms that the patent faces a presumption of invalidity that requires affirmative rebuttal through evidence of criticality or unexpected results.
The ruling puts pressure on pharmaceutical companies to document experimental evidence during development that demonstrates why specific ratios in the claimed range produce results that are both different from and superior to what adjacent ranges would yield. General showings that the formulation “works” or achieves a known property — like stabilizing an amorphous drug form — are not sufficient if that property was predictable from the prior art. For generic drug manufacturers seeking to challenge pioneer drug patents through Paragraph IV litigation or IPR proceedings, the decision provides a clear roadmap: find prior art with overlapping ranges, and the burden of proof shifts to the patentee.